Edwards Lifesciences (EW) analyst forecast and price target
Analyst forecast
Consensus of 31 analyst ratings
Based on 8 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Initiated Coverage | Overweight | $110.00 | Oct 7, 2026 |
| BTIG | Maintained | Buy | $110.00 | Sep 11, 2026 |
| UBS | Initiated Coverage | Neutral → Buy | $110.00 | Jul 28, 2026 |
| Piper Sandler | Maintained | Overweight | $101.00 from $100.00 | Jul 24, 2026 |
| JP Morgan | Maintained | Overweight | $105.00 from $100.00 | Jul 24, 2026 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $101.00 from $87.00 | Jul 24, 2026 |
| Truist Securities | Maintained | Hold | $95.00 from $90.00 | Jul 16, 2026 |
| Mizuho | Maintained | Outperform | $105.00 from $100.00 | Jul 15, 2026 |
| RBC Capital | Maintained | Outperform | $110.00 from $100.00 | Jul 13, 2026 |
| Citigroup | Maintained | Buy | $110.00 from $101.00 | Jul 8, 2026 |
| Evercore ISI Group | Maintained | Outperform | $100.00 from $93.00 | Jul 6, 2026 |
| BTIG | Maintained | Buy | $110.00 from $100.00 | Jun 30, 2026 |
| RBC Capital | Maintained | Outperform | $100.00 | Jun 16, 2026 |
| TD Cowen | Maintained | Buy | $104.00 from $97.00 | Jun 2, 2026 |
| Barclays | Maintained | Overweight | $110.00 from $104.00 | Apr 27, 2026 |
| Baird | Maintained | Neutral | $87.00 from $85.00 | Apr 24, 2026 |
| Canaccord Genuity | Maintained | Hold | $85.00 from $87.00 | Apr 24, 2026 |
| Truist Securities | Maintained | Hold | $90.00 from $89.00 | Apr 24, 2026 |
| Evercore ISI Group | Maintained | Outperform | $93.00 from $92.00 | Apr 24, 2026 |
| BTIG | Maintained | Buy | $100.00 from $98.00 | Apr 24, 2026 |
Frequently asked questions
What is the price target for EW stock?
The average 12-month analyst price target for Edwards Lifesciences (EW) is $104.63, with a high estimate of $110.00 and a low of $95.00, across 8 analysts.
Is EW a buy, sell, or hold?
Analysts covering Edwards Lifesciences currently average a Buy rating: 24 buy, 7 hold and 0 sell, from 31 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for EW?
The average price target of $104.63 implies 21.02% upside from the last price of $86.45.
What is the latest analyst rating on EW?
On Oct 7, 2026, Barclays initiated coverage of Edwards Lifesciences at Overweight with a price target of $110.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.